WO2023057548 - CCR6 RECEPTOR MODULATORS
National phase entry is expected:
Publication Number
WO/2023/057548
Publication Date
13.04.2023
International Application No.
PCT/EP2022/077776
International Filing Date
06.10.2022
Title **
[English]
CCR6 RECEPTOR MODULATORS
[French]
MODULATEURS DU RÉCEPTEUR CCR6
Applicants **
IDORSIA PHARMACEUTICALS LTD
Hegenheimermattweg 91
4123 Allschwil, CH
Inventors
AISSAOUI, Hamed
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil, CH
ALLEMANN, Oliver
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil, CH
CAROFF, Eva
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil, CH
MEYER, Emmanuel
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil, CH
RICHARD-BILDSTEIN, Sylvia
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil, CH
Priority Data
PCT/EP2021/077719
07.10.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2320 | |
| EPO | Filing, Examination | 9521 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 9810 |
Total: 22815 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory/autoimmune diseases/disorders and cancer.[French]
La présente invention concerne des composés de formule (I), leur synthèse et leur utilisation en tant que modulateurs du récepteur CCR6 pour la prévention ou le traitement, par exemple, de maladies/troubles inflammatoires/auto-immuns et du cancer.